News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
18
2025
-
03
Hospital-enterprise collaboration, a new chapter begins! Shandong Guojie Hospital visited Linyi Pharmaceutical, exploring new opportunities for cooperation!
Classification：
News
行业新闻
Corporate News
Amidst the vibrant atmosphere of springtime, an exchange event between the hospital and the company opened up new avenues for future cooperation. On the 17th, He Shiyong, general manager of Shandong Guojie Hospital, and his team visited L&N Pharma, where both sides engaged in in-depth discussions on multi-faceted cooperation opportunities, laying a solid foundation for joint efforts in advancing the development of the pharmaceutical and healthcare industry.
During the visit, General Manager He Shiyong and his team first toured the group's exhibition hall, learning in detail about the company's industrial layout, product lines, and future development direction. They expressed high recognition of L&N Pharma's technological strength in the field of chronic diseases. L&N Pharma expressed its hope to introduce more high-quality products to the hospital and serve patients. Both sides stated that they will further strengthen communication and explore more possibilities for cooperation in the future.
Pharmaceutical research and development should be clinically driven, and hospital-enterprise cooperation is an important way to promote the transformation of innovative achievements. This visit by General Manager He Shiyong of Guojie Hospital not only deepened mutual understanding but also opened up vast space for future cooperation. L&N Pharma will continue to be driven by technological research and development and guided by market demand, striving to achieve the sharing of resources and complementary advantages between hospitals and enterprises, jointly promoting the development of the medical industry, and providing a continuous stream of health solutions for patients.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China